Dale Miles PhD

Dr. Miles is a senior scientist in the Department of Clinical Pharmacology at Genentech. He leads clinical pharmacology efforts across the late stage oncology portfolio in heme, including polatuzumab vedotin, an ADC in clinical development for the treatment of NHL. Dr. Miles also leads the Pharmacology Subteam for polatuzumab vedotin, and is responsible for developing and implementing nonclinical strategies to support this molecule.

Prior to Genentech, Dr. Miles was an Executive Director at Exelixis Inc. supporting the clinical pharmacology for small molecule oncology drugs. Prior to Exelixis, he worked at Pharmacyclics Inc. as a Director of bioanalytical chemistry. Dr. Miles has published 30 peer-reviewed papers in the field of bioanalytical, drug metabolism and pharmacokinetics. Dr. Miles obtained his PhD and MS degrees in Chemical Engineering from Arizona State University, and his BS degree from Brigham Young University.